Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dovitinib + fulvestrant
- Development stage
- Phase 3
- Lead developer
- Allarity Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Dovitinib + fulvestrant is a combination therapy that pairs dovitinib, a potent inhibitor of fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR), with fulvestrant, a selective estrogen receptor antagonist. This combination was investigated for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer that had progressed during or after prior endocrine therapy. The combination showed promising clinical activity specifically in patients with FGF pathway amplification, with a median progression-free survival of 10.9 months versus 5.5 months in the placebo arm for this subgroup.
- Other names
- Dovitinib combined with fulvestrantDovitinib plus fulvestrant
02
Targets
ESR1 (ERα)ESR2 (ERβ)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on dovitinib + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dovitinib + fulvestrant.